First big drugs for 2024
New treatments for NASH, schizophrenia and more are on the way.
Welcome to the first Drug Pipeline Insights Report for 2024
Read the report for a review of:
- First approved drug for negative symptoms of schizophrenia
- First-in-class treatment for pulmonary arterial hypertension
- First FDA-approved drug for nonalcoholic steatohepatitis (NASH).
Don't want to read the full report? View the summary.
Related content
Optum Rx Drug Pipeline Insights Reports
Read the most recent quarterly reports on new drugs coming down the pipeline.
3 ways to deal with escalating drug costs
Innovations custom built for today’s specialty challenges.
Transforming the pharmacy industry with transparency
Hear how the industry’s most transparent and independent Pharmacy & Therapeutics Committee evaluates drugs for the Optum Rx formulary.